See more : Alexandria Real Estate Equities, Inc. (ARE) Income Statement Analysis – Financial Results
Complete financial analysis of Optimind Pharma Corp. (OMND.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Optimind Pharma Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Eduform’action Société Anonyme (MLMON.PA) Income Statement Analysis – Financial Results
- Williams Grand Prix Holdings PLC (WMGPF) Income Statement Analysis – Financial Results
- Prosper Engineering Public Company Limited (PROS.BK) Income Statement Analysis – Financial Results
- Secured Services, Inc. (SSVC) Income Statement Analysis – Financial Results
- CNS Pharmaceuticals, Inc. (CNSP) Income Statement Analysis – Financial Results
Optimind Pharma Corp. (OMND.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://optimindpharma.com
About Optimind Pharma Corp.
Optimind Pharma Corp. operates as a pharmaceutical company in Canada. The company offers psychedelic therapies for treatment of post-traumatic stress syndrome, anxiety, depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. It also operates a clinic that provides medical cannabis and other alternative treatments for various medical ailments, including ketamine-enhanced psychotherapy. The company is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 122.96K | 170.11K | 99.69K | 0.00 | 0.00 |
| Cost of Revenue | 64.40K | 118.24K | 36.00K | 0.00 | 0.00 |
| Gross Profit | 58.56K | 51.87K | 63.69K | 0.00 | 0.00 |
| Gross Profit Ratio | 47.62% | 30.49% | 63.89% | 0.00% | 0.00% |
| Research & Development | 120.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 668.98K | 911.63K | 436.77K | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -275.44K | 0.00 | 0.00 |
| SG&A | 668.98K | 911.63K | 161.32K | 79.41K | 40.09K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 791.84K | 1.37M | 161.32K | 79.41K | 40.09K |
| Cost & Expenses | 856.24K | 1.03M | 161.32K | 79.41K | 40.09K |
| Interest Income | 0.00 | 0.00 | 17.08K | 0.00 | 0.00 |
| Interest Expense | 91.30K | 74.34K | 11.36K | 45.19K | 135.34K |
| Depreciation & Amortization | 19.95K | 43.74K | 29.16K | 206.30K | 171.86K |
| EBITDA | -1.30M | -2.97M | -161.32K | 176.54K | 110.17K |
| EBITDA Ratio | -1,053.27% | -1,745.36% | -161.82% | 0.00% | 0.00% |
| Operating Income | -733.28K | -863.66K | -161.32K | -79.41K | -40.09K |
| Operating Income Ratio | -596.36% | -507.70% | -161.82% | 0.00% | 0.00% |
| Total Other Income/Expenses | -673.06K | -2.22M | -10.91K | 210.76K | 14.92K |
| Income Before Tax | -1.41M | -3.09M | -172.23K | 131.35K | -25.18K |
| Income Before Tax Ratio | -1,143.75% | -1,814.78% | -172.77% | 0.00% | 0.00% |
| Income Tax Expense | -8.76K | -8.85K | 143.52K | 0.00 | 0.00 |
| Net Income | -1.40M | -3.08M | -172.23K | 131.35K | -25.18K |
| Net Income Ratio | -1,136.63% | -1,809.57% | -172.77% | 0.00% | 0.00% |
| EPS | -0.01 | -0.04 | -0.03 | 0.04 | -0.01 |
| EPS Diluted | -0.01 | -0.04 | -0.03 | 0.04 | -0.01 |
| Weighted Avg Shares Out | 99.52M | 81.99M | 5.98M | 3.65M | 3.49M |
| Weighted Avg Shares Out (Dil) | 99.52M | 81.99M | 5.98M | 3.65M | 3.49M |
Source: https://incomestatements.info
Category: Stock Reports